Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 222

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer

Open access
Soliman, Pamela T., Westin, Shannon N., Dioun, Shayan, Sun, Charlotte C., Euscher, Elizabeth, Munsell, Mark F., Fleming, Nicole D., Levenback, Charles, Frumovitz, Michael, Ramirez, Pedro T., Lu, Karen H. · 2017 · Gynecologic Oncology

Abstract

Objective Sentinel lymph node (SLN) mapping continues to evolve in the surgical staging of endometrial cancer (EC). The purpose of this trial was to identify the sensitivity, false negative rate (FNR) and FN predictive value (FNPV) of SLN compared to complete pelvic and para-aortic lymphadenectomy (LAD) in women with high-risk EC. Methods Women with high-risk EC (grade 3, serous, clear cell, carcinosarcoma) were enrolled in this prospective surgical trial. All patients underwent preoperative PET/CT and intraoperative SLN biopsy followed by LAD. Patients with peritoneal disease on imaging or at the time of surgery were excluded. Patients were evaluable if SLN was attempted and complete LAD was performed. Results 123 patients were enrolled between 4/13 and 5/16; 101 were evaluable. At least 1 SLN was identified in 89% (90); bilateral detection 58%, unilateral pelvic 40%, para-aortic only 2%. Indocyanine green was used in 61%, blue dye in 28%, and blue dye and technetium in 11%. Twenty-three pts (23%) had ≥ 1 positive node. In 20/23, ≥ 1 SLN was identified and in 19/20 the SLN was positive. Only 1 patient had bilateral negative SLN and positive non-SLNs on final pathology. Overall, sensitivity of SLN was 95% (19/20), FNR was 5% (1/20) and FNPV was 1.4% (1/71). If side-specific LAD was performed when a SLN was not detected, the FNR decreased to 4.3% (1/23). Conclusion This prospective trial demonstrated that SLN biopsy plus side-specific LAD, when SLN is not detected, is a reasonable alternative to a complete LAD in high-risk endometrial cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2017.05.016

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 222

Metadata

Authors
Soliman, P. T., Westin, S. N., Dioun, S., Sun, C. C., Euscher, E., Munsell, M. F., Fleming, N. D., Levenback, C., Frumovitz, M., Ramirez, P. T., & Lu, K. H.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2017-08
Volume
146
Issue
2
Pages
234-239
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2614413038
Cited by
222
References
2
FWCI
24.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. https://app.cochat.ai/papers/10.1016/j.ygyno.2017.05.016
The paper
Soliman, P. T., Westin, S. N., Dioun, S., Sun, C. C., Euscher, E., Munsell, M. F., Fleming, N. D., Levenback, C., Frumovitz, M., Ramirez, P. T., & Lu, K. H. (2017). A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2017.05.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.